Qwest, Seacoast Banking Corp. of Florida: Early Volume Plays

Qwest and Seacoast Banking Corp. of Florida were among several stocks trading near $5 set to move on above-average volume Thursday.
Author:
Publish date:

NEW YORK (

TheStreet

) --

Qwest

(Q)

is one of several stocks trading near $5 poised to move on above-average volume Thursday after the telecom company agreed to a buyout that values shares at a 15% premium.

Qwest

shares were up 5.3% to $5.52 in the premarket session after

CenturyTel

(CTL) - Get Report

agreed to acquire the company.

Qwest shareholders will receive 0.1664 a share of CenturyTel for each share of Qwest common stock they own at closing, reflecting an enterprise value for Qwest of about $22.4 billion, including the assumption of $11.8 billion of Qwest debt. Qwest is being valued at $6.02 a CenturyTel share, a premium to Qwest shareholders of about 15% over Qwest's closing stock price Wednesday of $5.24.

The three-month average daily volume for Qwest is 26.51 million, according to Yahoo! Finance.

Elsewhere,

Seacoast Banking Corp. of Florida

(SBCF) - Get Report

rallied by 75 cents, or 38.5%, to $2.70 in the premarket session after the company said its first-quarter loss narrowed to 4 cents a share from 73 cents a share in the year-ago quarter, coming in better than the average analyst estimate that called for a loss of 14 cents a share.

Seacoast Banking Corp. of Florida

posted first-quarter revenue of $23.9 million, up 3.2% from a year earlier to top the consensus target of $21.8 million. The 50-day average daily volume for Seacoast Banking is 516,000, according to the

Nasdaq

.

Digital Ally

(DGLY) - Get Report

was also poised to trade higher after the company said late Wednesday it has received international contracts from South America and Middle East. The stock closed Wednesday at $1.82 but rose nearly 10% in the after-market session. The 50-day average daily volume for Digital Ally is 64,000.

Vical

(VICL)

jumped by 35 cents, or 9.9%, to $3.88 in the premarket session after the company said its TransVax cytomegalovirus (CMV) vaccine elicited sustained increases in cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant recipients.

A report on the full evaluation of viral load and clinical endpoints will come in the third quarter, Vical said. The 50-day average daily volume for Vical is 378,000.

-- Written by Robert Holmes in Boston

.

Check out all of Thursday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on

Twitter

and become a fan of TheStreet.com on

Facebook.